146 related articles for article (PubMed ID: 12639546)
1. Identification of a high-affinity phosphopeptide inhibitor of Stat3.
Ren Z; Cabell LA; Schaefer TS; McMurray JS
Bioorg Med Chem Lett; 2003 Feb; 13(4):633-6. PubMed ID: 12639546
[TBL] [Abstract][Full Text] [Related]
2. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation.
Turkson J; Ryan D; Kim JS; Zhang Y; Chen Z; Haura E; Laudano A; Sebti S; Hamilton AD; Jove R
J Biol Chem; 2001 Nov; 276(48):45443-55. PubMed ID: 11579100
[TBL] [Abstract][Full Text] [Related]
3. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity.
Turkson J; Kim JS; Zhang S; Yuan J; Huang M; Glenn M; Haura E; Sebti S; Hamilton AD; Jove R
Mol Cancer Ther; 2004 Mar; 3(3):261-9. PubMed ID: 15026546
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor.
Coleman DR; Ren Z; Mandal PK; Cameron AG; Dyer GA; Muranjan S; Campbell M; Chen X; McMurray JS
J Med Chem; 2005 Oct; 48(21):6661-70. PubMed ID: 16220982
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the binding of high affinity phosphopeptides to Stat3.
McMurray JS
Biopolymers; 2008; 90(1):69-79. PubMed ID: 18058821
[TBL] [Abstract][Full Text] [Related]
6. A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity.
Dourlat J; Liu WQ; Sancier F; Edmonds T; Pamonsinlapatham P; Cruzalegui F; Garbay C
Biochimie; 2009 Aug; 91(8):996-1002. PubMed ID: 19470402
[TBL] [Abstract][Full Text] [Related]
7. Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3.
Wiederkehr-Adam M; Ernst P; Müller K; Bieck E; Gombert FO; Ottl J; Graff P; Grossmüller F; Heim MH
J Biol Chem; 2003 May; 278(18):16117-28. PubMed ID: 12591923
[TBL] [Abstract][Full Text] [Related]
8. Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling.
Zhang T; Ma J; Cao X
Biochem J; 2003 Dec; 376(Pt 2):457-64. PubMed ID: 14498832
[TBL] [Abstract][Full Text] [Related]
9. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity.
Sun J; Blaskovich MA; Jove R; Livingston SK; Coppola D; Sebti SM
Oncogene; 2005 May; 24(20):3236-45. PubMed ID: 15735720
[TBL] [Abstract][Full Text] [Related]
10. Dimer stability as a determinant of differential DNA binding activity of Stat3 isoforms.
Park OK; Schaefer LK; Wang W; Schaefer TS
J Biol Chem; 2000 Oct; 275(41):32244-9. PubMed ID: 10915797
[TBL] [Abstract][Full Text] [Related]
11. A novel type of calmodulin interaction in the inhibition of basic helix-loop-helix transcription factors.
Onions J; Hermann S; Grundström T
Biochemistry; 2000 Apr; 39(15):4366-74. PubMed ID: 10757985
[TBL] [Abstract][Full Text] [Related]
12. Validating Stat3 in cancer therapy.
Darnell JE
Nat Med; 2005 Jun; 11(6):595-6. PubMed ID: 15937466
[No Abstract] [Full Text] [Related]
13. Structure-activity relationships of small phosphopeptides, inhibitors of Grb2 SH2 domain, and their prodrugs.
Liu WQ; Vidal M; Olszowy C; Million E; Lenoir C; Dhôtel H; Garbay C
J Med Chem; 2004 Feb; 47(5):1223-33. PubMed ID: 14971902
[TBL] [Abstract][Full Text] [Related]
14. Design and biological evaluation of linear and cyclic phosphopeptide ligands of the N-terminal SH2 domain of protein tyrosine phosphatase SHP-1.
Imhof D; Wieligmann K; Hampel K; Nothmann D; Zoda MS; Schmidt-Arras D; Zacharias M; Böhmer FD; Reissmann S
J Med Chem; 2005 Mar; 48(5):1528-39. PubMed ID: 15743195
[TBL] [Abstract][Full Text] [Related]
15. Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling.
Mandal PK; Limbrick D; Coleman DR; Dyer GA; Ren Z; Birtwistle JS; Xiong C; Chen X; Briggs JM; McMurray JS
J Med Chem; 2009 Apr; 52(8):2429-42. PubMed ID: 19334714
[TBL] [Abstract][Full Text] [Related]
16. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells.
Song H; Wang R; Wang S; Lin J
Proc Natl Acad Sci U S A; 2005 Mar; 102(13):4700-5. PubMed ID: 15781862
[TBL] [Abstract][Full Text] [Related]
17. Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling.
Buerger C; Groner B
J Cancer Res Clin Oncol; 2003 Dec; 129(12):669-75. PubMed ID: 13680379
[TBL] [Abstract][Full Text] [Related]
18. The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells.
Nikitakis NG; Hamburger AW; Sauk JJ
Cancer Res; 2002 Feb; 62(4):1004-7. PubMed ID: 11861373
[TBL] [Abstract][Full Text] [Related]
19. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
20. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells.
Nishimoto A; Yu Y; Lu Z; Mao X; Ren Z; Watowich SS; Mills GB; Liao WS; Chen X; Bast RC; Luo RZ
Cancer Res; 2005 Aug; 65(15):6701-10. PubMed ID: 16061651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
